PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
78.38%
Revenue growth of 78.38% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
140.18%
Gross profit growth of 140.18% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
12.00%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.16%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
12.00%
Operating income growth 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 9.33%. Mohnish Pabrai would confirm if scale economies are a factor.
14.27%
Net income growth of 14.27% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see potential if moderate gains can keep rising.
13.68%
EPS growth of 13.68% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
13.68%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.28%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.10%
OCF growth of 38.10% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
-23.74%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-428.58%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-428.58%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-428.58%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-115.04%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 7.46%. Seth Klarman might see a fundamental problem if peers maintain growth.
-115.04%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 3.15%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-115.04%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
123.15%
Equity/share CAGR of 123.15% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
123.15%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 8.62%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
123.15%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 17.27%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.45%
AR growth of 50.45% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
11.96%
Inventory growth of 11.96% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
-4.73%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-9.17%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.27%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.